Developing patient-derived organoids to demonstrate JX24120 inhibits SAMe synthesis in endometrial cancer by targeting MAT2B

• DOI: 10.1016/j.phrs.2024.107420
• Publication Date: 2024-09-17T21:27:32Z
• Authors: Chunxue Zhang; Xiaojing Lu; Ting Ni; Qi Wang; Xiaoyan Gao; Xiao Sun; Jian Li; Fei Mao; Jin Hou; Yudong Wang
• Keywords: Organoid

Endometrial cancer (EC) is one of the most common gynecologic malignancies, which lacking effective drugs for intractable conditions or patients unsuitable surgeries. Recently, patient-derived organoids (PDOs) are found feasible research and drug discoveries. Here, we established a series PDOs from EC performed repurposing screening mechanism analysis treatment. We confirmed that regulatory β subunit methionine adenosyltransferase (MAT2B) highly correlated with malignant progression in endometrial cancer. Through on PDOs, identify JX24120, chlorpromazine derivative, as specific inhibitor MAT2B, directly binds to MAT2B (K